IVVD logo

IVVD
Invivyd Inc

5,923
Mkt Cap
$356.48M
Volume
7.27M
52W High
$3.07
52W Low
$0.483
PE Ratio
-3.39
IVVD Fundamentals
Price
$1.21
Prev Close
$1.16
Open
$1.16
50D MA
$1.52
Beta
1.34
Avg. Volume
3.22M
EPS (Annual)
-$0.3048
P/B
1.69
Rev/Employee
$437,918.03
$201.17
Loading...
Loading...
News
all
press releases
IVVD Stock Tanks 19% Today – But This Analyst Believes It Has A Potential Upside Of Over 730%
Invivyd posted a first-quarter revenue of $13.7 million, sharply below Wall Street’s estimates of around $18 million, according to Fiscal.ai data.
Stocktwits·3d ago
News Placeholder
More News
News Placeholder
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates
Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of -62.50% and -25.30%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
News Placeholder
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates
Upstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +5.96% and +102.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
TELA Bio, Inc. (TELA) Reports Q1 Loss, Beats Revenue Estimates
TELA Bio (TELA) delivered earnings and revenue surprises of -50.00% and +3.02%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
News Placeholder
Invivyd (IVVD) Expected to Announce Quarterly Earnings on Thursday
Invivyd (NASDAQ:IVVD) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...
MarketBeat·17d ago
News Placeholder
Invivyd, Inc. (NASDAQ:IVVD) Receives Consensus Rating of "Hold" from Analysts
Shares of Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) have been given a consensus recommendation of "Hold" by the six research firms that are covering the company, MarketBeat reports. One equities...
MarketBeat·22d ago
News Placeholder
Invivyd Updates VYD2311 REVOLUTION Trials, Modestly Upsizes Study, Unveils Measles mAb VMS-063
Invivyd (NASDAQ:IVVD) provided updates on its REVOLUTION program for COVID-19 monoclonal antibody candidate VYD2311 and announced the discovery and early development work for a measles monoclonal antibody candidate, VMS-063, during a conference call led by board chairman Marc Elia alongside Chief Sc...
MarketBeat·1mo ago
News Placeholder
Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program
Invivyd expands VYD2311 COVID study, delays timeline to Q3 2026, and advances measles antibody VMS063 toward clinical development.read more...
Benzinga·1mo ago
News Placeholder
Invivyd, Inc. (NASDAQ:IVVD) Given Consensus Rating of "Hold" by Analysts
Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) has received an average rating of "Hold" from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and t...
MarketBeat·2mo ago
News Placeholder
FY2027 Earnings Estimate for Invivyd Issued By HC Wainwright
Invivyd, Inc. (NASDAQ:IVVD - Free Report) - HC Wainwright reduced their FY2027 EPS estimates for shares of Invivyd in a research report issued to clients and investors on Tuesday, March 10th. HC...
MarketBeat·2mo ago
<
1
2
...
>

Latest IVVD News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.